SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Stemline Therapeutics (STML)

Add STML Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 5/16/2016 12:20:06 PM - Followers: 10 - Board type: Free - Posts Today: 0

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients.

In a multicenter Phase 1/2 trial in patients with advanced hematologic cancer, SL-401 demonstrated single agent activity in multiple indications, including durable complete responses (CRs) in relapsed or refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), and an overall survival (OS) improvement relative to historical data in the most heavily pre-treated patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into a pivotal Phase 2b trial in patients with BPDCN and a registration-directed Phase 2b study in patients with advanced AML. In Phase 1/2 trials, Stemline's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs) in adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma, as well as an OS benefit in adult patients with refractory or recurrent glioblastoma compared with historical data. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer.

Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. Stemline also possesses a landmark portfolio of intellectual property that includes the earliest filings in the CSC field covering CSC-directed therapeutics, diagnostics, and drug discovery.

Stemline Therapeutics has developed a Discovery Platform called StemScreen® to identify novel compounds that target and kill CSCs.

StemScreen®-1 is a 3-step platform which involves:

1. CSC isolation and target identification.

2. Proprietary in silico screen which identifies compound classes that interact with CSC targets.

3. Battery of anti-CSC functional assays that test compounds for activity against CSCs both in vitro and in vivo. In some cases the Company has employed medicinal chemistry to optimize lead compounds. Stemline currently has 6 active oncology programs — three of which have yielded lead compounds to date.

StemScreen®-2 is a proprietary high throughput screen currently in development. StemScreen®-2 takes advantage of a landmark discovery that cancer cell lines harbor CSCs. This technology enables the development of high throughput screens for compounds that target CSCs.

Pre-Clinical Programs

Clinical Programs

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
STML News: Stemline Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference 09/23/2016 07:33:02 AM
STML News: Stemline Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference 09/07/2016 07:30:00 AM
STML News: Current Report Filing (8-k) 08/25/2016 07:31:49 AM
STML News: Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401 08/23/2016 07:30:00 AM
STML News: Stemline Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference 08/11/2016 07:00:00 AM
#29   Traded a small amount here, but long term floWteiuQ 05/16/16 12:20:06 PM
#28   Would like to see this hold over 6$ Cbdpotential 04/21/16 04:12:04 PM
#27   $STML Looking good Cbdpotential 04/21/16 04:10:58 PM
#26   bot starter in stml at $ $7.50 luvgrowth 12/22/15 11:35:15 AM
#25   Cut my loss stockmarkot 05/05/15 03:24:22 PM
#24   Im out! Too much pain stockmarkot 05/05/15 03:24:14 PM
#23   $STML under rader but not by analyst 5 stockmarkot 04/28/15 07:19:50 PM
#22   $STML recent news/filings stocktrademan 07/31/14 02:42:18 PM
#21   Roth Capital Reiterates Buy On Stemline Following Initiation maytepper 07/28/14 04:14:03 PM
#20   $STML $22.66 Bought a small position @ $21.39, $$$eeker 02/07/14 11:28:07 AM
#19   $STML Worth reading. $$$eeker 02/07/14 10:42:33 AM
#18   Check it our for yourselves: LPC47 12/02/13 08:38:21 PM
#17   Insiders making big buys at 20$ here. Very LPC47 12/02/13 06:41:46 PM
#16   Yes. Just watch ;) LPC47 12/02/13 06:39:57 PM
#15   Still thinking 50 eoy? Jordantrae 11/30/13 10:04:08 PM
#14   Stemline Therapeutics target raised to $70 at Aegis biocqr 10/30/13 01:36:39 PM
#13   Big gap up after the political dark clouds LPC47 10/10/13 03:03:38 PM
#12   Taking a big position here. Tremendous underwriting support. LPC47 10/10/13 02:48:14 PM
#11   Jefferies initiates Stemline Therapeutics with a Buy; shares higher biocqr 08/29/13 03:40:06 PM
#10   I thought it was very bullish. ronpopeil 08/14/13 10:35:15 AM
#9   Wedbush presentation... biocqr 08/14/13 10:32:18 AM
#8   They may have a replay on their website. ronpopeil 08/14/13 10:30:53 AM
#7   They may have a replay on their website. ronpopeil 08/14/13 10:30:48 AM
#6   Oh was it? i missed that ECole 08/14/13 10:27:25 AM
#5   I thought the presentation was very bullish ronpopeil 08/14/13 10:24:22 AM
#4   Wedbush 2013 Life Sciences Management Access Conference updates ECole 08/14/13 10:17:50 AM
#3   STML presentation @ JMP Healthcare conf... biocqr 07/10/13 11:18:44 AM
#2   SL-401 receives Orphan Drug designation in BPDCN. A DonShimoda 06/18/13 05:05:38 PM
#1   Stemline's June 2013 Corporate Presentation can be DonShimoda 06/18/13 05:01:46 PM